株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

メラノーマ(黒色腫):世界の治験動向

Melanoma Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 217232
出版日 ページ情報 英文 1302 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.48円で換算しております。
Back to Top
メラノーマ(黒色腫):世界の治験動向 Melanoma Global Clinical Trials Review, H2, 2017
出版日: 2017年12月28日 ページ情報: 英文 1302 Pages
概要

当レポートでは、メラノーマ治療薬の臨床試験におけるデータを提供、国別の動向、臨床試験数、世界における臨床実験所別の募集状況などをまとめた結果をお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 主要国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数:メラノーマ(黒色腫)治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:メラノーマ(黒色腫)治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - メラノーマ(黒色腫) 治療薬

有望な薬剤

  • 最新治験ニュース:メラノーマ(黒色腫)

治験プロファイルの基本情報

付録

図表一覧

目次
Product Code: GDHC4767CTIDB

GlobalData's clinical trial report, "Melanoma Global Clinical Trials Review, H2, 2017" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Melanoma to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Melanoma to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Melanoma Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Melanoma 30
  • Dec 13, 2017: Enrollment of First Patient in Investigator-Initiated Clinical Trial for Telomelysin (OBP-301) - pembrolizumab combination therapy 30
  • Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews 30
  • Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma 30
  • Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance 31
  • Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial 31
  • Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting 32
  • Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 32
  • Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 34
  • Nov 07, 2017: Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting 34
  • Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting 35
  • Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 35
  • Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics 36
  • Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 36
  • Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma 36
  • Clinical Trial Profile Snapshots 38

Appendix 1299

  • Abbreviations 1299
  • Definitions 1299
  • Research Methodology 1300
  • Secondary Research 1300
  • About GlobalData 1301
  • Contact Us 1301
  • Disclaimer 1301
  • Source 1302

List of Tables

List of Tables

  • Melanoma Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
  • Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
  • Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Melanoma Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
Back to Top